ArticleScience (New York, N.Y.)2024
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Radiotherapy followed by metformin neoadjuvant therapy drives superior pancreatic cancer ferroptosis and augments anti-tumor immunity.Fundamental research · 2026Article
- Recent developments in cancer immuno-interception strategies.Trends in molecular medicine · 2026Review
- CD5Science advances · 2026Article
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Pancreatic Cancer-Advances in the Last 50 Years.World journal of surgery · 2026Review
- Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming.Signal transduction and targeted therapy · 2026Article
- A plant vesicle-dendritic cell chimera for enhancing cancer immunotherapy.Nature communications · 2026Article
- The interplay between p21-activated kinases and tumour-infiltrating dendritic cells and T cells and its implication in pancreatic cancer immunotherapy.Cell communication and signaling : CCS · 2026Review
- Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
- Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity.Science (New York, N.Y.) · 2026Article
- Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment.Nature reviews. Cancer · 2026Review
- Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity.Molecular oncology · 2026Article
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Steps toward developing an algorithm to facilitate recognition of translational science.Journal of clinical and translational science · 2026Article
- Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor".Oncology research · 2026Review
- Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic.Frontiers in immunology · 2026Review
- Nanoscale metal-organic frameworks as a versatile platform for synergistic combination tumor therapy.Journal of nanobiotechnology · 2025Review
- Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer.Cancers · 2025Review
- Article
- The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway.Translational oncology · 2025Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Krishnan K MahadevanDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6503-6851
Allison M DyevoichDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4106-0435
Yang ChenDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4441-5614
Bingrui LiDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4807-1452
Hikaru SugimotoDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amari M SockwellDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0008-1963-4181
Kathleen M McAndrewsDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4092-4991
Lakshmi Kavitha SthanamDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8430-3505
Huamin WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2038-5863
Shabnam ShalapourDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4743-3706
Stephanie S WatowichDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1969-659X
Raghu KalluriDepartment of Cancer Biology, Metastasis Research Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2190-547X
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MDefining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory ActivityR01AI133822 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2018 to 2022
$2.1MRegulation and function of nonlymphoid organ CD103 dendritic cellsR01AI109294 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2015 to 2019
$2.0MClinical Significance of Pancreatic Cancer Differentiation and DedifferentiationR01CA195651 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, HUAMIN · 2015 to 2021
$1.8MMechanisms associated with organotropic metastasisR01CA252729 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2021 to 2022
$1.1MNCI NIH HHS P01 CA117969NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA195651NCI NIH HHS R01 CA252729NIAID NIH HHS R01 AI109294NIAID NIH HHS R01 AI133822
Abstract
Inflammation and tissue damage associated with pancreatitis can precede or occur concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC coupled with pancreatitis (ptPDAC), antigen-presenting type I conventional dendritic cells (cDC1s) are specifically activated. Immune checkpoint blockade therapy (iCBT) leads to cytotoxic CD8
Indexed as
Carcinoma, Pancreatic DuctalDendritic CellsImmunotherapyPancreatic NeoplasmsTumor MicroenvironmentAnimalsCancer VaccinesCD8-Positive T-LymphocytesImmune Checkpoint InhibitorsMiceMice, Inbred C57BLPancreatitisCancer VaccinesImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.